Latrepirdine not effective in Huntington's disease

November 1, 2012
Latrepirdine not effective in huntington's disease
Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease, according to a study published online Oct. 29 in the Archives of Neurology.

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according to a study published online Oct. 29 in the Archives of Neurology.

Karl Kieburtz, M.D., M.P.H., and colleagues from the HORIZON Investigators of the Study Group and the European Huntington's Disease Network, conducted a six-month, randomized, double-blind study of latrepirdine, 20 mg three times daily, versus placebo in 403 patients with mild-to-moderate HD, across 64 research centers in Australia, Europe, and North America. The effect of latrepirdine on cognition and global function was assessed.

The researchers observed no significant difference between latrepirdine-treated patients and placebo-treated patients in the mean change in the Mini-Mental State Examination score (1.5- and 1.3-point improvement, respectively). There was also no significant difference in the distribution of the Clinician Interview-Based Impression of Change, plus carer interview between the groups (P = 0.84). There were no significant differences on secondary efficacy outcomes measures of behavior, daily function, motor function, and safety. There was a similar incidence of adverse events for latrepirdine- and placebo-treated patients.

"In patients with mild-to-moderate HD and , treatment with latrepirdine for six months was safe and well tolerated but did not improve cognition or global function relative to placebo," the authors write.

Several authors disclosed to pharmaceutical companies, including Medivation and Pfizer, both of which supported the study and manufacture latrepirdine.

Explore further: Reach2HD, a Phase II study in Huntington's disease, launched

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Reach2HD, a Phase II study in Huntington's disease, launched

June 7, 2012
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) ...

Donepezil found helpful in dementia with lewy bodies

July 31, 2012
(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

April 11, 2011
An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease, according to a report posted online today that will appear in the ...

New drug seems well-tolerated and merits further investigation in patients with Huntington's disease

November 7, 2011
A novel drug (pridopidine) that stabilises dopamine signalling in areas of the brain that control movement and coordination, appears well tolerated and warrants further study in patients with Huntington's disease (HD), a ...

Rejected Alzheimer's drug shows new potential

July 31, 2012
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped ...

Recommended for you

Theory: Flexibility is at the heart of human intelligence

November 19, 2017
Centuries of study have yielded many theories about how the brain gives rise to human intelligence. Some neuroscientists think intelligence springs from a single region or neural network. Others argue that metabolism or the ...

Investigating patterns of degeneration in Alzheimer's disease

November 17, 2017
Alzheimer's disease (AD) is known to cause memory loss and cognitive decline, but other functions of the brain can remain intact. The reasons cells in some brain regions degenerate while others are protected is largely unknown. ...

Study may point to new treatment approach for ASD

November 17, 2017
Using sophisticated genome mining and gene manipulation techniques, researchers at Vanderbilt University Medical Center (VUMC) have solved a mystery that could lead to a new treatment approach for autism spectrum disorder ...

Paraplegic rats walk and regain feeling after stem cell treatment

November 16, 2017
Engineered tissue containing human stem cells has allowed paraplegic rats to walk independently and regain sensory perception. The implanted rats also show some degree of healing in their spinal cords. The research, published ...

Brain implant tested in human patients found to improve memory recall

November 15, 2017
(Medical Xpress)—A team of researchers with the University of Southern California and the Wake Forest School of Medicine has conducted experiments involving implanting electrodes into the brains of human volunteers to see ...

Researchers identify potential mediator for social memory formation

November 15, 2017
Research by a group of scientists at the Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have discovered that a tiny brain region plays a critical role in the formation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.